WATERTOWN, Mass.--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe ...
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory ...
WATERTOWN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Abata Therapeutics, a company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced ...
BOSTON--(BUSINESS WIRE)--Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and ...
Abata Therapeutics has launched with $95 million in series A funding to take cell therapy into a new realm: the treatment of multiple sclerosis. The investment comes primarily from Third Rock Ventures ...
Abata Therapeutics will bring three programs into the clinic by the end of 2025 for progressive Multiple Sclerosis, Type 1 diabetes and inclusion body myositis. (Abata) () After three and a half years ...
(MENAFN- GlobeNewsWire - Nasdaq) First open IND for Abata's best-in-class autologous T cell receptor (TCR)-Treg cell therapy platform for autoimmune disease Expected initiation of first-in-human Phase ...
CEO Samantha Singer said Abata Therapeutics Inc. “spent a considerable amount of time finding the right indication” for its approach, which deploys autologous regulatory T cells (Tregs) made to ...
(MENAFN- GlobeNewsWire - Nasdaq) Dr. Beck's extensive experience in CMC and product development will be instrumental as Abata enters clinical development this year WATERTOWN, Mass., Sept. 16, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results